Robert Kapito - IShares Pharmaceuticals Trustee
IHE Etf | USD 70.20 0.76 1.09% |
Mr. Robert S. Kapito serves as Trustee of Ishares Dow Jones US Pharmaceuticals Index Fund since 2009. Mr. Kapito has served as a Director of iShares, Inc. since 2009, a Director of iShares MSCI Russia Capped Index Fund, Inc. since 2010 and a Director of BlackRock, Inc. since 2007. In addition, he has over 20 years of experience as part of BlackRock, Inc. and BlackRocks predecessor entities. Mr. Kapito serves as President and Director of BlackRock, Inc., and is the Chairman of the Operating Committee, a member of the Office of the Chairman, the Leadership Committee and the Corporationrationrate Council. He is responsible for daytoday oversight of BlackRocks key operating units, including the Account Management and Portfolio Management Groups, Real Estate Group and BlackRock Solutions. Prior to assuming his current responsibilities in 2007, Mr. Kapito served as Head of BlackRocks Portfolio Management Group. In that role, he was responsible for overseeing all portfolio management within BlackRock, including the Fixed Income, Equity, Liquidity, and Alternative Investment Groups. Mr. Kapito serves as a member of the Board of Trustees of the University of Pennsylvania. He is also President of the Board of Directors for the Hope Heroes Childrens Cancer Fund since 2002 and President of the Board of Directors for Periwinkle Theatre for Youth, a national nonprofit artsin education organization, since 1983
Age | 62 |
Tenure | 16 years |
Professional Marks | MBA |
Issuer | iShares |
Inception Date | 2006-05-01 |
Benchmark | Dow Jones U.S. Select Pharmaceuticals Index |
Entity Type | Regulated Investment Company |
Asset Under Management | 625.09 Million |
Average Trading Valume | 73,919.5 |
Asset Type | Equity |
Category | Sector |
Focus | Health Care |
Market Concentration | Developed Markets |
Similar Fund Executives
Showing other executives | One Year Return | ||
Philip Nussbaum | Invesco Dynamic Pharmaceuticals | 51 | |
Keith Ovitt | Invesco Dynamic Pharmaceuticals | 49 | |
Charles Hurty | iShares Insurance ETF | 72 | |
Matthew Flaherty | SPDR SP Pharmaceuticals | 41 | |
Eilleen Clavere | iShares Healthcare ETF | 60 | |
John Martinez | iShares Healthcare ETF | 55 | |
Kevin Gustafson | Invesco Dynamic Pharmaceuticals | 42 | |
Dave Kelly | SPDR SP Pharmaceuticals | N/A | |
Madhav Rajan | iShares Insurance ETF | 52 | |
Helen Peters | SPDR SP Pharmaceuticals | 71 | |
Scott Zoltowski | SPDR SP Pharmaceuticals | 43 | |
John Clark | SPDR SP Pharmaceuticals | 45 | |
Cecilia Herbert | iShares Insurance ETF | 67 | |
Gary French | SPDR SP Pharmaceuticals | 67 | |
Donald Wilson | Invesco Dynamic Pharmaceuticals | 54 | |
Cecilia Herbert | iShares Healthcare ETF | 67 | |
Peter Ambrosini | SPDR SP Pharmaceuticals | 68 | |
Chad Hallett | SPDR SP Pharmaceuticals | 46 | |
John Kerrigan | iShares Healthcare ETF | 60 | |
Madhav Rajan | iShares Healthcare ETF | 52 | |
Marc Kole | Invesco Dynamic Pharmaceuticals | 52 |
iShares Pharmaceuticals Money Managers
Geoffrey Flynn, Chief Operating Officer, Executive Vice President | ||
Robert Silver, Independent Trustee | ||
John Kerrigan, Independent Trustee | ||
Madhav Rajan, Independent Trustee | ||
Matt Tucker, Vice President | ||
Cecilia Herbert, Independent Trustee | ||
Michael Latham, President Trustee | ||
Jack Gee, Chief Financial Officer, Treasurer | ||
Charles Hurty, Independent Trustee | ||
Eilleen Clavere, Secretary | ||
George Parker, Independent Chairman of the Board of Trustees | ||
John Martinez, Independent Trustee | ||
Amy Schioldager, Executive Vice President | ||
Robert Kapito, Trustee | ||
Ira Shapiro, Vice President Chief Legal Officer |
IShares Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is IShares Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Price To Earning | 22.36 X | |||
Price To Book | 1.56 X | |||
Price To Sales | 3.32 X | |||
Number Of Employees | 15 | |||
Beta | 0.58 | |||
Total Asset | 381.08 M | |||
One Year Return | 10.90 % | |||
Three Year Return | 4.80 % | |||
Five Year Return | 7.20 % | |||
Ten Year Return | 4.50 % |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iShares Pharmaceuticals is a strong investment it is important to analyze IShares Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact IShares Pharmaceuticals' future performance. For an informed investment choice regarding IShares Etf, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Pharmaceuticals ETF. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
The market value of iShares Pharmaceuticals is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is IShares Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Pharmaceuticals' market value can be influenced by many factors that don't directly affect IShares Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.